Adaptimmune Therapeutics plc
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2022 | $-141.8M | $-171.3M | $29.5M | $18.2M |
| FY2023 | $-140.9M | $-145.6M | $4.7M | $11.8M |
| FY2024 | $-73.2M | $-74.1M | $886.0K | $12.1M |
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2022 | $-141.8M | $-171.3M | $29.5M | $18.2M |
| FY2023 | $-140.9M | $-145.6M | $4.7M | $11.8M |
| FY2024 | $-73.2M | $-74.1M | $886.0K | $12.1M |